[Federal Register Volume 87, Number 40 (Tuesday, March 1, 2022)]
[Notices]
[Pages 11451-11452]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04245]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Development and 
Commercialization of Chimeric Antigen Receptor T-Cell Therapies (CAR-T) 
That are Specific to CD22 and Other B-Cell Antigens for the Treatment 
of B-Cell Malignancies

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the Patents and Patent Applications listed in 
the Supplementary Information section of this Notice to Syncopation 
Life Sciences Inc., (``Syncopation''), located in Palo Alto, 
California.

DATES: Only written comments and/or complete applications for a license 
which are received by the National Cancer Institute's Technology 
Transfer Center on or before March 16, 2022 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
and comments relating to the contemplated Exclusive Patent License 
should be directed to: Jim Knabb, Senior Technology Transfer Manager, 
at Telephone: (240)-276-7856; or at email: [email protected].

SUPPLEMENTARY INFORMATION: 

Intellectual Property

E-080-2012-0: Human Monoclonal Antibodies Specific for CD22

    1. US Provisional Patent Application 61/042,329, filed April 4, 
2008 (E-080-2008-0-US-01);
    2. International Patent Application PCT/US2009/039,080, Filed April 
1, 2009 (E-080-2008/0-PCT-02);
    3. US Patent Application: 12/934,214, filed September 23, 2010 (E-
080-2008-0-US-03);
    4. US Patent Application 13/959,061, filed August 5, 2015 (E-080-
2008-0-US-04);
    5. US Patent Application 15/012,023, filed February 1, 2016 (E-080-
2008-0-US-05);
    6. US Patent Application 15/424,238, filed February 3, 2017 (E-080-
2008-0-US-06).

E-291-2012-0: M971 Chimeric Antigen Receptors

    1. US Provisional Patent Application 61/717,960, filed October 24, 
2012 (E-291-2012-0-US-01);
    2. International Patent Application PCT/US2013/060332, filed 
September 18, 2013 (E-291-2012-0-PCT-02);
    3. Australia Application No: 2019235926, filed September 2, 2020 
(E-291-2012-0-AU-03);
    4. Brazil Patent Application BR112015009003-6, filed April 22, 2015 
(E-291-2012-0-BR-04);
    5. Canada Application No: 2889055, filed September 18, 2013 (E-291-
2012-0-CA-05);
    6. China Application No: 201380061387.5, filed May 25, 2015 (E-291-
2012-0-CN-06);
    7. European Patent Application No: 13773468.7, filed September 18, 
2013 (E-291-2012-0-EP-07);
    8. India Patent Application No: 2344/CHENP/2015, filed September 
18, 2013 (E-291-2012-0-IN-08);
    9. Japan Application No: 539602/2015, filed April 24, 2015 (E-291-
2012-0-JP-09);
    10. Russia Patent Application: 2015117237, filed May 7, 2015 (E-
291-2012-0-RU-10);
    11. US Patent Application: 14/437,889, filed April 23, 2015 (E-291-
2012-0-US-11);
    12. Hong Kong Patent Application: 16101891.0, filed February 19, 
2016 (E-291-2012-0-HK-12);
    13. Russia Patent Application: 2018116582, filed May 4, 2018 (E-
291-2012-0-RU-13);
    14. Japan Patent Application: 2018-088908, filed May 2, 2018, (E-
291-2012-0-JP-14);
    15. Australia Patent Application: 2018204257, filed June 14, 2018 
(E-291-2012-0-AU-16);
    16. US Patent Application: 16/107,271, filed August 21, 2018 (E-
291-2012-0-US-17);
    17. Germany Patent Application: 13773468.7, filed April 22, 2015 
(E-291-2012-0-DE-18);
    18. Spain Patent Application: 13773468.7, filed April 22, 2015 (E-
291-2012-0-ES-19);
    19. France Patent Application: 13773468.7, filed April 22, 2015 (E-
291-2012-0-FR-20);
    20. Great Britain Patent Application: 13773468.7, filed April 22, 
2015 (E-291-2012-0-GB-21);
    21. Italy Patent Application: 13773468.7, filed April 22, 2015 (E-
291-2012-0-IT-22);
    22. China Patent Application: 201910500128.7, filed June 11, 2019 
(E-291-2012-0-CN-23);
    23. US Patent Application: 16/869,792, filed May 8, 2020 (E-291-
2012-0-US-24).

E-017-2017-0: CD19/CD22 Bicistronic CAR Targeting Human B-Cell 
Malignancies

    1. US Provisional Patent Application No.: 62/135,442, filed May 15, 
2017 (E-017-2017-0-US-01);
    2. International Patent Application PCT/US2018/032,809, filed May 
15, 2018 (E-017-2017-0-PCT-02);
    3. Australia Patent Application No.: 2018269194, filed October 28, 
2019 (E-017-2017-0-AU-03);
    4. Canada Patent Application No: 3062433, filed May 15, 2018 (E-
017-2017-0-CA-04);

[[Page 11452]]

    5. China Patent Application No.: 201880032676.5, filed Date: May 
15, 2018 (E-017-2017-0-CN-05);
    6. European Patent Application No.: 18733012.1, filed May 15, 2018 
(E-017-2017-0-EP-06);
    7. Japan Patent Application No.: 2019-563082, filed November 13, 
2019 (E-017-2017-0-JP-07);
    8. Korea Patent Application No.: 2019-7017289, filed December 13, 
2019, (E-017-2017-0-KR-08);
    9. Singapore Patent Application No.: 11201910499V, filed November 
11, 2019 (E-017-2017-0-SG-09);
    10. United States Patent Application No.: 16/613,187, filed 
November 13, 2019 (E-017-2017-0-US-10);
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be worldwide, and 
the fields of use may be limited to the following:
    ``Development, manufacture and commercialization of chimeric 
antigen receptor T cell (CAR-T) immunotherapies for the treatment of B 
cell malignancies, wherein the T cells are:
    1. Manufactured ex vivo;
    2. Not engineered to overexpress CD47;
    3. Engineered to express a CAR that targets CD22 via the m971 scFv 
in combination with both:
    a. Binders, CARs, or other receptors targeting: CD19, CD20, CD79b, 
or any combination thereof; and
    b. At least one of the following:
--A technology to activate CD2 signaling in the CAR T cell, and/or
--Manufacturing of the cell product using the Storage by Actuated 
Shuttling (StASh)
    Where ``ex vivo'' specifically means where the cells or tissue are 
removed from a healthy donor (in the case of allogeneic therapy) or the 
patient (in the case of autologous therapy), modified ex vivo and then, 
implanted, transplanted, infused, or transferred into the patient.
    For purposes of clarity, specifically excluded from these Fields of 
Use are the following:
    1. Allogeneically-derived CAR-T immunotherapies that have been 
engineered to overexpress CD47;
    2. CAR-T immunotherapies wherein the CAR-T cells are manufactured 
within the patient via gene therapy vectors delivered to the patient 
(in vivo CAR-T immunotherapies);
    3. Autologously-derived CAR-T immunotherapies that have been 
engineered to be specific for CD19, CD20, and CD22 (via the m971 scFv) 
absent the engineering of the CAR-T therapies to activate CD2 signaling 
and/or StASh as described in the Fields of Use 3(b) above;
    4. CAR-T immunotherapies wherein the CAR-T cells are engineered to 
express a bispecific CAR that is engineered to bind to CD19 and CD22, 
as described in HHS Ref. E-106-2015 and encompassing the m971 scFv and 
the CD22 CAR.''
    The government-owned technologies that are contemplated in this 
proposed license are CAR therapies that target CD22 by utilizing the 
anti-CD22 binder known as m971 alone. The E-080-2008 technology 
encompasses the m971 binder, while E-291-2012 describes a CAR 
encompassing the m971 binder. Additionally, E-017-2017 describes a 
bicistronic CAR vector that encompasses the CD22-targeting m971 CAR and 
a CAR that targets CD19. CD22 is expressed on the surface of B cells in 
B cell malignancies and CD22-targeting CAR-T has shown early promise in 
clinical trials for ALL and NHL both as a monospecific and 
multispecific therapy. Targeting CD22 in combination with other B cell 
antigens (CD19, CD20, and/or CD79b in this instance) can lead to more 
effective CAR-T cell therapies.
    This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published Notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information from these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: February 23, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2022-04245 Filed 2-28-22; 8:45 am]
BILLING CODE 4140-01-P